SIAT® Immunogenicity Risk Assessment

Immunogenicity against therapeutic molecules, such as antibody drugs, is a clinical challenge in the successful treatment of many diseases. Therefore, immunogenicity risk assessment in preclinical settings will be useful to improve the efficacy and safety of products-based therapeutics in the development stages. As a first-class provider in the immunologic analysis fields, Creative Biolabs has established Sensitive Immunogenicity Assessment Technology® (SIAT®) system, with attention to in vivo models and assays used to mitigate this risk. Notably, we provide a variety of testing services to therapeutic protein immunogenicity risk assessment, which helps clients harvest more critical information on drug immune safety in the preclinical phase that could be valuable in the success of the drug.


Therapeutic antibodies and proteins may cause an immune response of bodies, leading to the occurrence of anti-drug antibodies (ADAs). Nowadays, therapeutic antibody drugs have significantly promoted the management of numerous chronic diseases and severe disorders. However, their optimal clinical application and further development are complicated by the induction of undesired immune responses. Therapeutic agent-induced ADAs can alter drug pharmacokinetics (PK) and pharmacodynamics (PD) resulting in impaired efficacy and occasionally safety problems. Over the past decade, a growing interest in investigating novel methods to assess the risk of unwanted immunogenicity during preclinical drug development, with the aim to reduce the risk upon the molecular design phase, clinical development, and when drug products reach the market.

SIAT® Immunogenicity Risk Assessment Services at Creative Biolabs

The purpose of immunogenicity studies is to characterize an immune response to the product and to identify correlations between ADAs and PK & PD, as well as efficacy & safety. As such, immunogenicity assessment should be contained in the planning of the key clinical trials, including the synchronization of sampling for ADAs and relevant biomarkers, if available, along with the evaluation of efficacy and safety.

The immunological cascade leading to ADA formation. Fig.1 The immunological cascade leading to ADA formation. (Tourdot, 2019)

Acquiring information on the immunogenic property of a drug prior to clinical trials is pivotal to avoid patient risks and attrition owing to costly drug failure. At Creative Biolabs, we bring a comprehensive meaning to immunogenicity and provide innovative services for preclinical immunogenicity risk assessment of therapeutic antibody drugs. Our current applicable strategies encompass in silico and in vitro methods to understanding the immunological risks associated with interactions of the treatment with crucial classes of immune cells (e.g. T cells, B cells, and antigen-presenting cells).


The planning and evaluation of immunogenicity risk of a biological product have been realized as multidisciplinary exercises. This risk assessment can evolve through the lifecycle of therapeutic protein and may be used to support applications at every step of product development. As an expert in the immune market, Creative Biolabs helps global clients decide the best way to assess immunogenicity of specific biologics using a series of advanced immunogenicity assays. For more information, please directly contact us or discuss with our experts today.


  1. Tourdot, S.; et al. Nonclinical immunogenicity risk assessment of therapeutic proteins. Bioanalysis. 2019.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Online Inquiry


Call us at:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us